Congress extends diabetes research funding for Type 1 patients and Native Americans
S. 2211 — Special Diabetes Program Reauthorization Act of 2025 · Filed by Susan Collins (R-ME) · 34 cosponsors · Introduced Jul 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill extends federal funding for two existing diabetes research and treatment programs: the Special Diabetes Program for Type 1 Diabetes and the Special Diabetes Program for Indians. It authorizes $160 million annually for fiscal years 2026–2027 for each program, plus an additional $40 million for the final quarter of 2027 (October–December), allowing the programs to continue their work on prevention, treatment, and management of diabetes in these populations.
Why we flagged it
The bill is a straightforward reauthorization and funding extension for two established federal diabetes programs. It contains no policy changes, no new restrictions, and no private carve-outs—only appropriations authority to continue existing services.
Who it affects
The bill extends funding for established public-health programs serving people with Type 1 diabetes and Native American communities, enabling continued research, treatment, and prevention services. No restrictions on citizen rights or remedies are imposed; the mechanism is straightforward appropriation to support existing federal health infrastructure.
Named in the bill
Special Diabetes Program for Type 1 Diabetes, Special Diabetes Program for Indians, Public Health Service Act, Section 330B, Section 330C
Where it stands
34 cosponsors: 23 Democrats, 11 Republicans.
- Jul 8, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Jul 8, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Dec 2025 to Dec 2025. Those filings disclosed $290,000 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 0% of bills with at least one filing.
Susan Collins, the sponsor, reported $2,459,513 in PAC receipts in the 2026 cycle.
- Breakthrough T1d (formerly Known As Jdrf Intl.) — $290,000 on 1 filing
Lobbying Disclosure Act filings through Jan 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (1,197 characters) on Jun 3, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Dec 2025. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jan 20, 2026 · page rendered 2026-10-20.
“Congress extends diabetes research funding for Type 1 patients and Native Americans” QuorumCivic. https://share.quorumcivic.app/bill/119/s2211 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.